ORIC PHARMACEUTICALS, INC. Payments to Acquire Marketable Securities
ORIC PHARMACEUTICALS, INC. (ORIC) reported Payments to Acquire Marketable Securities of $124.64 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2020-11-05
- 2020-09-30: Payments to Acquire Marketable Securities 9 month $124.64M.
| Period end | Payments to Acquire Marketable Securities 9 month |
|---|---|
| 2020-09-30 | $124.64M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |